Mutation Analysis (MutSig v1.5)
Kidney Chromophobe (Primary solid tumor)
17 October 2014 | analyses__2014_10_17
Maintainer Information
Citation Information
doi:10.7908/C13777KK
Maintained by David Heiman (Broad Institute)
Cite as Broad Institute TCGA Genome Data Analysis Center (2014): Mutation Analysis (MutSig v1.5). Broad Institute of MIT and Harvard. doi:10.7908/C13777KK
Overview
Introduction

This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v1.5 was used to generate the results found in this report.

- Working with individual set: KICH-TP

- Number of patients in set: 66

Input

The input for this pipeline is a set of individuals with the following files associated for each:

1. An annotated .maf file describing the mutations called for the respective individual, and their properties.

2. A .wig file that contains information about the coverage of the sample.

Summary

- MAF used for this analysis:KICH-TP.final_analysis_set.maf

- Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt

- Significantly mutated genes (q ≤ 0.1): 30

- Mutations seen in COSMIC: 43

- Significantly mutated genes in COSMIC territory: 2

- Significantly mutated genesets: 31

- Significantly mutated genesets: (excluding sig. mutated genes):0

Mutation Preprocessing

- Read 66 MAFs of type "Baylor-Illumina"

- Total number of mutations in input MAFs: 7559

- After removing 34 mutations outside chr1-24: 7525

- After removing 520 blacklisted mutations: 7005

- After removing 225 noncoding mutations: 6780

- After collapsing adjacent/redundant mutations: 6767

Mutation Filtering

- Number of mutations before filtering: 6767

- After removing 282 mutations outside gene set: 6485

- After removing 92 mutations outside category set: 6393

- After removing 1 "impossible" mutations in

- gene-patient-category bins of zero coverage: 6018

Results
Breakdown of Mutations by Type

Table 1. Get Full Table Table representing breakdown of mutations by type.

type | count
--- | ---
Frame_Shift_Del | 181
Frame_Shift_Ins | 218
In_Frame_Del | 53
In_Frame_Ins | 18
Missense_Mutation | 3904
Nonsense_Mutation | 172
Silent | 1741
Splice_Site | 106
Total | 6393

Breakdown of Mutation Rates by Category Type

Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.

category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio
--- | --- | --- | --- | --- | --- | ---
*CpG->T | 1158 | 113882076 | 1e-05 | 10 | 4.6 | 2.1
A->G | 1170 | 1020035596 | 1.1e-06 | 1.1 | 0.51 | 2.3
*Cp(A/C/T)->T | 587 | 947255610 | 6.2e-07 | 0.62 | 0.28 | 1.7
transver | 987 | 2081173282 | 4.7e-07 | 0.47 | 0.21 | 5
indel+null | 666 | 2081173282 | 3.2e-07 | 0.32 | 0.14 | NaN
double_null | 83 | 2081173282 | 4e-08 | 0.04 | 0.018 | NaN
Total | 4651 | 2081173282 | 2.2e-06 | 2.2 | 1 | 3.5

Target Coverage for Each Individual

The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom). If the figure is unpopulated, then full coverage is assumed (e.g. MutSig CV doesn't use WIGs and assumes full coverage).

Figure 1.

Distribution of Mutation Counts, Coverage, and Mutation Rates Across Samples

Figure 2. Patients counts and rates file used to generate this plot: KICH-TP.patients.counts_and_rates.txt

Lego Plots

The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.

Figure 3. Get High-res Image SNV Mutation rate lego plot for entire set. Each bin is normalized by base coverage for that bin. Colors represent the six SNV types on the upper right. The three-base context for each mutation is labeled in the 4x4 legend on the lower right. The fractional breakdown of SNV counts is shown in the pie chart on the upper left. If this figure is blank, not enough information was provided in the MAF to generate it.

Figure 4. Get High-res Image SNV Mutation rate lego plots for 4 slices of mutation allele fraction (0<=AF<0.1, 0.1<=AF<0.25, 0.25<=AF<0.5, & 0.5<=AF) . The color code and three-base context legends are the same as the previous figure. If this figure is blank, not enough information was provided in the MAF to generate it.

CoMut Plot

Figure 5. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.

Significantly Mutated Genes

Column Descriptions:

- N = number of sequenced bases in this gene across the individual set

- n = number of (nonsilent) mutations in this gene across the individual set

- npat = number of patients (individuals) with at least one nonsilent mutation

- nsite = number of unique sites having a non-silent mutation

- nsil = number of silent mutations in this gene across the individual set

- n1 = number of nonsilent mutations of type: *CpG->T

- n2 = number of nonsilent mutations of type: A->G

- n3 = number of nonsilent mutations of type: *Cp(A/C/T)->T

- n4 = number of nonsilent mutations of type: transver

- n5 = number of nonsilent mutations of type: indel+null

- n6 = number of nonsilent mutations of type: double_null

- p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene

- p = p-value (overall)

- q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 30. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).

rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | TP53 | tumor protein p53 | 85573 | 28 | 22 | 26 | 1 | 3 | 3 | 4 | 7 | 10 | 1 | 0.0024 | 4e-15 | 4.8e-11
2 | FRG1 | FSHD region gene 1 | 53658 | 14 | 12 | 13 | 3 | 1 | 3 | 5 | 1 | 3 | 1 | 0.25 | 7.6e-15 | 4.8e-11
3 | MUC4 | mucin 4, cell surface associated | 233000 | 101 | 44 | 97 | 28 | 20 | 24 | 25 | 31 | 1 | 0 | 0.073 | 7.7e-15 | 4.8e-11
4 | PABPC1 | poly(A) binding protein, cytoplasmic 1 | 129689 | 7 | 7 | 6 | 0 | 1 | 1 | 2 | 0 | 1 | 2 | 0.23 | 4.2e-10 | 1.6e-06
5 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 79261 | 7 | 6 | 7 | 0 | 0 | 1 | 0 | 1 | 3 | 2 | 0.49 | 4.2e-10 | 1.6e-06
6 | GOLGA6L6 | golgin A6 family-like 6 | 64194 | 6 | 6 | 5 | 0 | 1 | 0 | 1 | 3 | 1 | 0 | 0.34 | 2.5e-09 | 7.9e-06
7 | TAS2R43 | taste receptor, type 2, member 43 | 51426 | 5 | 5 | 5 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0.24 | 8.4e-09 | 0.000021
8 | PABPC3 | poly(A) binding protein, cytoplasmic 3 | 125375 | 9 | 7 | 9 | 1 | 3 | 3 | 2 | 1 | 0 | 0 | 0.14 | 9e-09 | 0.000021
9 | CDC27 | cell division cycle 27 homolog (S. cerevisiae) | 154221 | 7 | 6 | 7 | 1 | 1 | 1 | 3 | 1 | 1 | 0 | 0.28 | 5.8e-08 | 0.00012
10 | HLA-A | major histocompatibility complex, class I, A | 70491 | 5 | 5 | 5 | 0 | 0 | 0 | 1 | 3 | 1 | 0 | 0.26 | 1.4e-07 | 0.00026
11 | OR1S2 | olfactory receptor, family 1, subfamily S, member 2 | 64746 | 4 | 4 | 4 | 1 | 0 | 1 | 3 | 0 | 0 | 0 | 0.33 | 1.2e-06 | 0.002
12 | OR5M9 | olfactory receptor, family 5, subfamily M, member 9 | 61710 | 4 | 4 | 4 | 0 | 1 | 1 | 0 | 2 | 0 | 0 | 0.3 | 2.9e-06 | 0.0045
13 | SDHA | succinate dehydrogenase complex, subunit A, flavoprotein (Fp) | 131182 | 6 | 5 | 6 | 0 | 1 | 0 | 3 | 2 | 0 | 0 | 0.1 | 3.2e-06 | 0.0045
14 | FAM86B1 | family with sequence similarity 86, member B1 | 44150 | 3 | 3 | 3 | 0 | 2 | 0 | 0 | 0 | 1 | 0 | 0.27 | 0.000013 | 0.017
15 | TEKT4 | tektin 4 | 56304 | 3 | 3 | 3 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 0.65 | 0.000016 | 0.02
16 | MAGEC1 | melanoma antigen family C, 1 | 224484 | 6 | 5 | 6 | 1 | 0 | 0 | 2 | 4 | 0 | 0 | 0.51 | 0.000023 | 0.027
17 | PRSS3 | protease, serine, 3 | 57102 | 8 | 7 | 6 | 4 | 1 | 1 | 1 | 2 | 3 | 0 | 0.66 | 0.000031 | 0.033
18 | OR13C2 | olfactory receptor, family 13, subfamily C, member 2 | 63360 | 3 | 3 | 3 | 1 | 0 | 0 | 2 | 0 | 1 | 0 | 0.67 | 0.000036 | 0.038
19 | FAM157B |  | 57343 | 3 | 3 | 3 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0.39 | 0.000064 | 0.058
20 | CCDC74A | coiled-coil domain containing 74A | 70775 | 4 | 3 | 4 | 0 | 2 | 0 | 0 | 1 | 1 | 0 | 0.4 | 0.000065 | 0.058
21 | POTEE | POTE ankyrin domain family, member E | 216226 | 5 | 5 | 5 | 1 | 1 | 1 | 0 | 2 | 1 | 0 | 0.59 | 0.000066 | 0.058
22 | TAS2R30 | taste receptor, type 2, member 30 | 63624 | 6 | 5 | 5 | 2 | 0 | 2 | 1 | 1 | 2 | 0 | 0.83 | 0.000069 | 0.058
23 | MAP1LC3A | microtubule-associated protein 1 light chain 3 alpha | 21983 | 2 | 2 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0.42 | 0.000071 | 0.058
24 | SIRPB1 | signal-regulatory protein beta 1 | 127341 | 4 | 4 | 4 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 0.24 | 0.000077 | 0.06
25 | CDKN1A | cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 29948 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.8 | 0.000086 | 0.064
26 | HSP90AB1 | heat shock protein 90kDa alpha (cytosolic), class B member 1 | 144891 | 4 | 4 | 4 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 0.31 | 0.000092 | 0.065
27 | ZNF799 | zinc finger protein 799 | 128554 | 5 | 4 | 5 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0.22 | 0.000094 | 0.065
28 | PCDHB10 | protocadherin beta 10 | 126521 | 5 | 4 | 4 | 0 | 1 | 1 | 1 | 2 | 0 | 0 | 0.16 | 0.00011 | 0.07
29 | OR10H2 | olfactory receptor, family 10, subfamily H, member 2 | 62832 | 3 | 3 | 3 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0.59 | 0.00011 | 0.07
30 | ZNF98 | zinc finger protein 98 (F7175) | 114314 | 4 | 3 | 3 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0.37 | 0.00016 | 0.096
31 | AQP7 | aquaporin 7 | 69551 | 6 | 3 | 6 | 1 | 1 | 0 | 0 | 5 | 0 | 0 | 0.43 | 0.00019 | 0.12
32 | FAM184A | family with sequence similarity 184, member A | 221159 | 4 | 4 | 4 | 0 | 1 | 2 | 0 | 0 | 1 | 0 | 0.34 | 0.00025 | 0.15
33 | SPCS1 | signal peptidase complex subunit 1 homolog (S. cerevisiae) | 18930 | 2 | 2 | 2 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0.57 | 0.00026 | 0.15
34 | HGC6.3 |  | 34103 | 2 | 2 | 2 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0.5 | 0.00027 | 0.15
35 | HNF1A | HNF1 homeobox A | 123995 | 3 | 3 | 3 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 0.56 | 0.00028 | 0.15

COSMIC analyses

In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.

Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 2. Number of genes displayed: 10

rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | TP53 | tumor protein p53 | 28 | 356 | 24 | 23496 | 2567 | 5.3e-13 | 2.4e-09
2 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 7 | 767 | 7 | 50622 | 36 | 4.4e-11 | 9.9e-08
3 | RCN1 | reticulocalbin 1, EF-hand calcium binding domain | 1 | 1 | 1 | 66 | 1 | 0.00015 | 0.22
4 | CENPC1 | centromere protein C 1 | 1 | 2 | 1 | 132 | 1 | 0.00029 | 0.33
5 | ALPK2 | alpha-kinase 2 | 1 | 3 | 1 | 198 | 1 | 0.00044 | 0.33
6 | SMARCC2 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily c, member 2 | 2 | 3 | 1 | 198 | 1 | 0.00044 | 0.33
7 | DDR2 | discoidin domain receptor tyrosine kinase 2 | 1 | 4 | 1 | 264 | 1 | 0.00059 | 0.38
8 | RB1 | retinoblastoma 1 (including osteosarcoma) | 2 | 267 | 2 | 17622 | 4 | 0.00076 | 0.4
9 | DCLK3 | doublecortin-like kinase 3 | 1 | 6 | 1 | 396 | 1 | 0.00088 | 0.4
10 | FLT4 | fms-related tyrosine kinase 4 | 4 | 6 | 1 | 396 | 1 | 0.00088 | 0.4

Note:

n - number of (nonsilent) mutations in this gene across the individual set.

cos = number of unique mutated sites in this gene in COSMIC

n_cos = overlap between n and cos.

N_cos = number of individuals times cos.

cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.

p = p-value for seeing the observed amount of overlap in this gene)

q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)

Geneset Analyses

Table 5. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 31. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | P53HYPOXIAPATHWAY | Hypoxia induces p53 accumulation and consequent apoptosis with p53-mediated cell cycle arrest, which is present under conditions of DNA damage. | ABCB1, AKT1, ATM, BAX, CDKN1A, CPB2, CSNK1A1, CSNK1D, FHL2, GADD45A, HIC1, HIF1A, HSPA1A, HSPCA, IGFBP3, MAPK8, MDM2, NFKBIB, NQO1, TP53 | 19 | ATM(3), CDKN1A(2), NFKBIB(1), TP53(28) | 2134520 | 34 | 24 | 32 | 1 | 6 | 3 | 4 | 8 | 11 | 2 | 0.00052 | 3.3e-15 | 4.7e-13
2 | G1PATHWAY | CDK4/6-cyclin D and CDK2-cyclin E phosphorylate Rb, which allows the transcription of genes needed for the G1/S cell cycle transition. | ABL1, ATM, ATR, CCNA1, CCND1, CCNE1, CDC2, CDC25A, CDK2, CDK4, CDK6, CDKN1A, CDKN1B, CDKN2A, CDKN2B, DHFR, E2F1, GSK3B, HDAC1, MADH3, MADH4, RB1, SKP2, TFDP1, TGFB1, TGFB2, TGFB3, TP53 | 25 | ABL1(1), ATM(3), ATR(2), CDK6(1), CDKN1A(2), CDKN1B(1), RB1(2), TGFB2(1), TP53(28) | 2965387 | 41 | 27 | 39 | 2 | 6 | 6 | 4 | 8 | 13 | 4 | 0.00065 | 5.4e-15 | 4.7e-13
3 | RBPATHWAY | The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. | ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH | 12 | ATM(3), CDC25C(1), MYT1(1), RB1(2), TP53(28), WEE1(1) | 1768224 | 36 | 25 | 34 | 1 | 5 | 4 | 5 | 9 | 10 | 3 | 0.00074 | 6.4e-15 | 4.7e-13
4 | PMLPATHWAY | Ring-shaped PML nuclear bodies regulate transcription and are required co-activators in p53- and DAXX-mediated apoptosis. | CREBBP, DAXX, HRAS, PAX3, PML, PRAM-1, RARA, RB1, SIRT1, SP100, TNF, TNFRSF1A, TNFRSF1B, TNFRSF6, TNFSF6, TP53, UBL1 | 13 | PAX3(1), PML(1), RB1(2), SIRT1(2), TP53(28) | 1877723 | 34 | 25 | 32 | 4 | 4 | 3 | 4 | 7 | 13 | 3 | 0.033 | 6.6e-15 | 4.7e-13
5 | ARFPATHWAY | Cyclin-dependent kinase inhibitor 2A is a tumor suppressor that induces G1 arrest and can activate the p53 pathway, leading to G2/M arrest. | ABL1, CDKN2A, E2F1, MDM2, MYC, PIK3CA, PIK3R1, POLR1A, POLR1B, POLR1C, POLR1D, RAC1, RB1, TBX2, TP53, TWIST1 | 16 | ABL1(1), MYC(1), PIK3R1(1), POLR1A(1), POLR1D(1), RB1(2), TP53(28) | 1963704 | 35 | 24 | 33 | 1 | 4 | 4 | 5 | 8 | 11 | 3 | 0.00052 | 6.6e-15 | 4.7e-13
6 | TERTPATHWAY | hTERC, the RNA subunit of telomerase, and hTERT, the catalytic protein subunit, are required for telomerase activity and are overexpressed in many cancers. | HDAC1, MAX, MYC, SP1, SP3, TP53, WT1, ZNF42 | 7 | MYC(1), TP53(28) | 697656 | 29 | 23 | 27 | 1 | 3 | 3 | 4 | 7 | 11 | 1 | 0.0013 | 6.8e-15 | 4.7e-13
7 | TIDPATHWAY | On ligand binding, interferon gamma receptors stimulate JAK2 kinase to phosphorylate STAT transcription factors, which promote expression of interferon responsive genes. | DNAJA3, HSPA1A, IFNG, IFNGR1, IFNGR2, IKBKB, JAK2, LIN7A, NFKB1, NFKBIA, RB1, RELA, TIP-1, TNF, TNFRSF1A, TNFRSF1B, TP53, USH1C, WT1 | 18 | IKBKB(1), JAK2(1), RB1(2), TP53(28) | 1928715 | 32 | 23 | 30 | 1 | 4 | 4 | 4 | 7 | 10 | 3 | 0.00072 | 6.9e-15 | 4.7e-13
8 | P53PATHWAY | p53 induces cell cycle arrest or apoptosis under conditions of DNA damage. | APAF1, ATM, BAX, BCL2, CCND1, CCNE1, CDK2, CDK4, CDKN1A, E2F1, GADD45A, MDM2, PCNA, RB1, TIMP3, TP53 | 16 | ATM(3), CDKN1A(2), PCNA(1), RB1(2), TP53(28) | 1801915 | 36 | 24 | 34 | 1 | 5 | 3 | 4 | 9 | 11 | 4 | 0.001 | 7e-15 | 4.7e-13
9 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | ARF3(1), CDKN1A(2), CDKN1B(1), TP53(28) | 805992 | 32 | 24 | 30 | 3 | 3 | 3 | 4 | 7 | 13 | 2 | 0.012 | 7.7e-15 | 4.7e-13
10 | RNAPATHWAY | dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. | CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 | 9 | CHUK(1), TP53(28) | 1018591 | 29 | 22 | 27 | 1 | 3 | 3 | 4 | 7 | 11 | 1 | 0.0017 | 7.7e-15 | 4.7e-13

Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10

rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
1 | HSA00300_LYSINE_BIOSYNTHESIS | Genes involved in lysine biosynthesis | AADAT, AASDHPPT, AASS, KARS | 4 | AADAT(1), AASDHPPT(1), AASS(2) | 471045 | 4 | 4 | 4 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0.25 | 0.0046 | 0.94
2 | SPPAPATHWAY | Thrombin cleaves protease-activated receptors PAR1 and PAR4 to induce calcium influx and activate platelet aggregation, a process inhibited by aspirin. | F2, F2R, F2RL3, GNAI1, GNB1, GNGT1, HRAS, ITGA1, ITGB1, MAP2K1, MAPK1, MAPK3, PLA2G4A, PLCB1, PRKCA, PRKCB1, PTGS1, PTK2, RAF1, SRC, SYK, TBXAS1 | 21 | F2R(1), F2RL3(1), GNAI1(1), ITGB1(1), MAPK3(2), PLCB1(1), PTK2(1), RAF1(1), SRC(1), SYK(1) | 2414919 | 11 | 10 | 11 | 0 | 3 | 3 | 3 | 1 | 1 | 0 | 0.023 | 0.0057 | 0.94
3 | IL3PATHWAY | IL-3 promotes proliferation and differentiation of hematopoietic cells via a heterodimeric receptor that activates the Stat5 and MAP kinase pathways. | CSF2RB, FOS, GRB2, HRAS, IL3, IL3RA, JAK2, MAP2K1, MAPK3, PTPN6, RAF1, SHC1, SOS1, STAT5A, STAT5B | 15 | CSF2RB(3), JAK2(1), MAPK3(2), RAF1(1), SHC1(1), STAT5B(1) | 1807799 | 9 | 9 | 9 | 0 | 2 | 4 | 0 | 3 | 0 | 0 | 0.074 | 0.007 | 0.94
4 | OXIDATIVE_PHOSPHORYLATION |  | ATP12A, ATP4B, ATP5E, ATP5O, ATP6AP1, ATP6V0A1, ATP6V0A4, ATP6V0B, ATP6V0C, ATP6V0C, SHMT1, ATP6V0D1, ATP6V0E, ATP6V1A, ATP6V1B1, ATP6V1B2, ATP6V1C1, ATP6V1C2, ATP6V1D, ATP6V1E1, ATP6V1F, ATP6V1G1, ATP6V1G2, ATP6V1G3, ATP6V1H, ATP7A, ATP7B, COX10, COX4I1, COX5A, COX5B, COX6A1, COX6A2, COX6B1, COX6C, COX7A1, COX7A2, COX7B, COX7C, COX8A, NDUFA1, NDUFA10, NDUFA11, NDUFA4, NDUFA5, NDUFA8, NDUFB2, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFS1, NDUFS2, NDUFV1, NDUFV2, PP, PPA2, SDHA, SDHA, SDHAL2, SDHB, UQCRB, UQCRC1, UQCRFS1, UQCRH | 59 | ATP12A(1), ATP5E(1), ATP6AP1(1), ATP6V0A1(1), ATP6V0A4(2), ATP6V1A(1), ATP6V1B1(1), ATP6V1B2(1), ATP7A(1), COX7A1(1), NDUFB5(1), NDUFS1(2), UQCRFS1(1) | 3683151 | 15 | 14 | 15 | 1 | 2 | 7 | 0 | 4 | 1 | 1 | 0.066 | 0.008 | 0.94
5 | ASBCELLPATHWAY | B cells require interaction with helper T cells to produce antigen-specific immunoglobulins as a key element of the human immune response. | CD28, CD4, CD80, HLA-DRA, HLA-DRB1, IL10, IL2, IL4, TNFRSF5, TNFRSF6, TNFSF5, TNFSF6 | 8 | CD80(1), HLA-DRB1(5) | 391735 | 6 | 5 | 6 | 2 | 1 | 1 | 3 | 1 | 0 | 0 | 0.49 | 0.01 | 0.94
6 | PTENPATHWAY | PTEN suppresses AKT-induced cell proliferation and antagonizes the action of PI3K. | AKT1, BCAR1, CDKN1B, FOXO3A, GRB2, ILK, ITGB1, MAPK1, MAPK3, PDK2, PDPK1, PIK3CA, PIK3R1, PTEN, PTK2, SHC1, SOS1, TNFSF6 | 15 | BCAR1(2), CDKN1B(1), ITGB1(1), MAPK3(2), PDK2(1), PIK3R1(1), PTK2(1), SHC1(1) | 1878331 | 10 | 9 | 10 | 1 | 3 | 1 | 1 | 2 | 2 | 1 | 0.27 | 0.012 | 0.94
7 | RBPATHWAY | The ATM protein kinase recognizes DNA damage and blocks cell cycle progression by phosphorylating chk1 and p53, which normally inhibits Rb to allow G1/S transitions. | ATM, CDC2, CDC25A, CDC25B, CDC25C, CDK2, CDK4, CHEK1, MYT1, RB1, TP53, WEE1, YWHAH | 11 | ATM(3), CDC25C(1), MYT1(1), RB1(2), WEE1(1) | 1682651 | 8 | 7 | 8 | 0 | 2 | 1 | 1 | 2 | 0 | 2 | 0.17 | 0.012 | 0.94
8 | HSA00531_GLYCOSAMINOGLYCAN_DEGRADATION | Genes involved in glycosaminoglycan degradation | ARSB, GALNS, GLB1, GNS, GUSB, HEXA, HEXB, HGSNAT, HPSE, HPSE2, HYAL1, HYAL2, IDS, IDUA, LCT, NAGLU, SPAM1 | 17 | GALNS(4), GNS(2), HEXA(1), HGSNAT(1), HPSE2(1), LCT(2), SPAM1(1) | 2085688 | 12 | 9 | 12 | 1 | 4 | 3 | 2 | 0 | 3 | 0 | 0.11 | 0.017 | 0.94
9 | LYSINE_BIOSYNTHESIS |  | AADAT, AASDH, AASDHPPT, AASS, KARS | 5 | AADAT(1), AASDHPPT(1), AASS(2) | 692071 | 4 | 4 | 4 | 0 | 0 | 2 | 1 | 1 | 0 | 0 | 0.25 | 0.018 | 0.94
10 | GLYCOSAMINOGLYCAN_DEGRADATION |  | ARSB, GALNS, GLB1, GNS, GUSB, HEXA, HEXB, IDS, IDUA, LCT, NAGLU | 11 | GALNS(4), GNS(2), HEXA(1), LCT(2) | 1446301 | 9 | 7 | 9 | 1 | 2 | 2 | 2 | 0 | 3 | 0 | 0.24 | 0.018 | 0.94

Methods & Data
Methods

In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]

Download Results

In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.

- Analysis Results (MD5 checksum)

- Auxiliary Data (MD5 checksum)

- MAGE-TAB File (MD5 checksum)

References
[1] TCGA, Integrated genomic analyses of ovarian carcinoma, Nature 474:609 - 615 (2011)
Copyright © 2015 Broad Institute TCGA GDAC as part of the TCGA Research Network. All rights reserved.
Made with Nozzle